Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin. The post The Slide in Ocugen Could Be a Slide to a Homerun appeared first on InvestorPlace.

The Slide in Ocugen Could Be a Slide to a Homerun

This biotech is targeting a lucrative market, but it may be too late for the company.

Why This Meme Stock Isn't Worth the Trouble

BioNTech SE

Cassava Sciences Inc

3 Biotech Stocks That Have More Than Tripled so far This Year

Revenue may not be right around the corner.

3 Things About Ocugen That Smart Investors Know

While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition. The post Ocugen Proves Groupthink Is a Double-Edged Sword appeared first on InvestorPlace.

Ocugen Proves Groupthink Is a Double-Edged Sword

A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices. The post Ocugen Needs More Than Covaxin to Boost Its Falling Shares appeared first on InvestorPlace.

Ocugen Needs More Than Covaxin to Boost Its Falling Shares

OCGN stock doesn't deserve the investment it receives and doesn't have much gas left in the tank at this point. The post As OCGN Stock Trudges Along Without Real Hope Must Wane appeared first on InvestorPlace.

As OCGN Stock Trudges Along Without Real Hope Must Wane

The company needs clear regulatory wins in the U.S. and Canada.

Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy

Ocugen aims to be among the first to carve out market share.

Is Ocugen About to Beat Moderna in This One Market?

Ocugen has been trying to commercialize a Covid-19 vaccine. However, many obstacles remain.

WHO's Nod Can't Mask Ocugen's Flimsy Fundamentals

Beyond Meat

DraftKings

Robinhood

Meta Materials

MicroVision

Peloton

So, which ones are stocks to sell ASAP? With these seven stocks, all former favorites on both Main Street and Wall Street, consider it high time to take the money and run.

7 Stocks To Sell Before They Head to The Market Graveyard

Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids?

OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids. The post OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today appeared first on InvestorPlace.

OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q3 2021 Results - Earnings Call Transcript

Affirm

AMC Entertainment

Root

SNDL Inc.

SunPower

Aggressive investors looking to profit off of the recent impressive volatility in certain companies may want to consider these meme stocks. The post 7 Meme Stocks Ready to Regain Their Lost Momentum appeared first on InvestorPlace.

7 Meme Stocks Ready to Regain Their Lost Momentum

As Ocugen - or at least, a partner in developing a Covid-19 vaccine - receives a critical approval, OCGN stock could rebound soon. The post Sell-the-News Moment Is Your Chance to Reload on Ocugen appeared first on InvestorPlace.

Sell-the-News Moment Is Your Chance to Reload on Ocugen

Conference Call and Webcast Today at 8:30 a.m. ET

Ocugen Provides Business Update and Third Quarter 2021 Financial Results

Modifier gene therapy platform has potential to treat multiple retinal diseases with one product Modifier gene therapy platform has potential to treat multiple retinal diseases with one product

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration

Most likely in the doldrums, but it could be temporary.

Where Will Ocugen Be in 3 Years?

After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock. The post Ocugen Stock Looks Poised to Take a Tumble Right Here appeared first on InvestorPlace.

Ocugen Stock Looks Poised to Take a Tumble Right Here

It'll take more than regulatory approvals of its vaccine for it to become a good investment.

Is Ocugen a Buy?

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 1.79% yesterday. This is why it happened.

Ocugen (OCGN) Stock: Why The Price Increased

Ocugen Inc (NASDAQ: OCGN) said that it sent a request to the FDA for an emergency authorization for its COVID-19 vaccine candidate BBV152, known as Covaxin outside of the US, for just pediatric use. The vaccine candidate is a whole-virion, inactivated vaccine and recently authorized by the WHO, developed by the Indian Company Bharat Biotech.

Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids

With its chances of experiencing another sharp slide in price likely. If you own OCGN stock today, cash out ASAP to avoid holding the bag.

With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News'

Moderna

Novavax

Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week.

News for Ocugen, Inc. Stock (OCGN)